This clinical trial is focused on studying a type of cancer called Diffuse Large B-Cell Lymphoma, which is a common form of non-Hodgkin lymphoma. The study is comparing two treatment options for patients who are 80 years or older, or those who are frail and 75 years or older. The treatments being compared are called R-MINI-CHOP and R-MINI-CHP combined with a medication known as Polatuzumab Vedotin (also referred to by its code name RO5541077). The purpose of the study is to evaluate how effective the combination of Polatuzumab Vedotin with R-MINI-CHP is compared to R-MINI-CHOP.

The medications involved in this study include Vincristine Sulfate, Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone, and Rituximab. These are commonly used in chemotherapy, which is a type of cancer treatment that uses drugs to destroy cancer cells. The study will involve administering these medications through different methods such as intravenous infusion, which means delivering the medication directly into a vein, and subcutaneous injection, which involves injecting the medication under the skin.

Participants in the study will receive one of the treatment options over a period of time, and their health will be monitored to see how well the treatment works. The study will look at various outcomes, such as how long patients live without the disease getting worse, the duration of response to the treatment, and the overall survival rate. The study will also assess the safety of the treatments and their impact on the quality of life of the participants. The trial is expected to continue until the end of 2025.